P95 has appointed Henk Hoornaert as Chief Commercial Officer (CCO). After two years of accelerated growth, this appointment will strengthen P95’s structure and improve business development, marking a further step towards a more stable and mature organization.

Henk Hoornaert holds a Master in Physical Education and a Postgraduate degree in Economics from the University of Leuven. He developed a vast career in the pharma sector, from medical representative in 1992, to product manager, local and then regional marketing team lead for Pfizer’s portfolios, including Cardiovascular, Alzheimer and Inflammation. During the last 3 years, Henk has been General Manager, first in Belgium and Luxembourg for Upjohn, a Pfizer division, and later in Austria and Switzerland at Viatris. 

P95 CEO Thomas Verstraeten reacts: “As we are nearing the end of 2021, we have made good progress in strengthening P95, and we have the opportunity to invest in improving our structures and hiring for new positions. Needless to say that Henk knows the pharma industry inside-out and his vast commercial and managerial experience will strengthen the management team significantly. As CCO, Henk will help us set up a commercial framework to support our ever-growing range and number of projects.”

P95 appoints Henk Hoornaert as Chief Commercial Officer

P95 has appointed Henk Hoornaert as Chief Commercial Officer (CCO). After two years of accelerated growth, this appointment will strengthen P95’s structure and improve business development, marking a further step towards a more stable and mature organization.

Henk Hoornaert holds a Master in Physical Education and a Postgraduate degree in Economics from the University of Leuven. He developed a vast career in the pharma sector, from medical representative in 1992, to product manager, local and then regional marketing team lead for Pfizer’s portfolios, including Cardiovascular, Alzheimer and Inflammation. During the last 3 years, Henk has been General Manager, first in Belgium and Luxembourg for Upjohn, a Pfizer division, and later in Austria and Switzerland at Viatris. 

P95 CEO Thomas Verstraeten reacts: “As we are nearing the end of 2021, we have made good progress in strengthening P95, and we have the opportunity to invest in improving our structures and hiring for new positions. Needless to say that Henk knows the pharma industry inside-out and his vast commercial and managerial experience will strengthen the management team significantly. As CCO, Henk will help us set up a commercial framework to support our ever-growing range and number of projects.”